65,437 trials
Healthy
Primary: Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an…
Acute Coronary Disease · Angina Unstable
Primary: First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison — 557; 522; 222; 226 participants — p=0.3037
Healthy
Primary: Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma) — 6.54; 6.06 ng/mL
Healthy
Primary: Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma) — 67.69; 74.33 ng/mL
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1c Change From Baseline — -1.3; -1.9; -1.4 Percent
Diabetes Mellitus · Dyslipidemias
Primary: The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol. — 3.2; -0.3 mg/dL — p=0.0018
Myopia
Primary: Comfort After Insertion — 7.9 Scale of 1 to 10
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies) · Healthy Subjects (Treated With no Diabetes Therapies)
Primary: Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During "Current Use" Period) - Time on Drug Analysis — 219.7; 226.7; 56.2 Cases per 100,000…
Constriction, Pathologic
Primary: Technical Success for Delivery — 100 Percentage of successful implantations
Hodgkin's Disease
Primary: Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF — 0.68; 0.32 proportion of participants
Type 2 Diabetes Mellitus, Non Insulin Dependent · Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in HbA1c at Week 30 — -0.47; -0.54 Percent
Hypercholesterolemia
Primary: Number of Participants With Adverse Events and Adverse Reactions — 141; 61 Participants
Non-Small-Cell Lung Carcinoma
Primary: Median Number of Months of Progression-free Survival (PFS) — 4.40; 4.24 Months — p=0.2358
Gastroesophageal Reflux
Primary: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter — 4.65; 3.31 hours — p=0.095
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score — 57.9; 58.2; 37.5; 28.3 OAB-q Score — p=<0.0001